Moleculin Biotech Inc (NASDAQ:MBRX) shares rose 5.6% on Friday . The company traded as high as $0.76 and last traded at $0.76, approximately 814,557 shares changed hands during mid-day trading. A decline of 7% from the average daily volume of 872,318 shares. The stock had previously closed at $0.72.

MBRX has been the topic of a number of research analyst reports. Oppenheimer began coverage on Moleculin Biotech in a research note on Thursday, October 17th. They issued an “outperform” rating and a $2.00 price target on the stock. Zacks Investment Research upgraded Moleculin Biotech from a “sell” rating to a “hold” rating in a research report on Tuesday, December 31st. ValuEngine upgraded Moleculin Biotech from a “hold” rating to a “buy” rating in a research report on Thursday, February 6th. Finally, Roth Capital reiterated a “buy” rating on shares of Moleculin Biotech in a research report on Monday, November 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $2.50.

The company has a current ratio of 1.67, a quick ratio of 1.67 and a debt-to-equity ratio of 0.02. The stock has a market cap of $34.75 million, a P/E ratio of -2.11 and a beta of 1.85. The firm has a 50-day simple moving average of $0.91 and a two-hundred day simple moving average of $1.04.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). Sell-side analysts predict that Moleculin Biotech Inc will post -0.44 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the business. Millennium Management LLC bought a new position in Moleculin Biotech during the 3rd quarter worth $237,000. Vanguard Group Inc. increased its position in shares of Moleculin Biotech by 235.4% in the second quarter. Vanguard Group Inc. now owns 2,680,010 shares of the company’s stock worth $3,350,000 after purchasing an additional 1,880,961 shares during the period. BlackRock Inc. increased its position in shares of Moleculin Biotech by 134.8% in the second quarter. BlackRock Inc. now owns 112,572 shares of the company’s stock worth $141,000 after purchasing an additional 64,632 shares during the period. Morgan Stanley increased its position in shares of Moleculin Biotech by 151.7% in the second quarter. Morgan Stanley now owns 31,411 shares of the company’s stock worth $39,000 after purchasing an additional 18,933 shares during the period. Finally, Renaissance Technologies LLC increased its position in shares of Moleculin Biotech by 7.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,007,364 shares of the company’s stock worth $922,000 after purchasing an additional 72,100 shares during the period. Hedge funds and other institutional investors own 10.01% of the company’s stock.

About Moleculin Biotech (NASDAQ:MBRX)

Moleculin Biotech, Inc, a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies.

Featured Article: Market Indexes

Receive News & Ratings for Moleculin Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moleculin Biotech and related companies with MarketBeat.com's FREE daily email newsletter.